American Century Companies Inc. Decreases Position in Supernus Pharmaceuticals, Inc. $SUPN

American Century Companies Inc. trimmed its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 44.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 509,368 shares of the specialty pharmaceutical company’s stock after selling 406,786 shares during the period. American Century Companies Inc. owned approximately 0.89% of Supernus Pharmaceuticals worth $24,343,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Royal Bank of Canada raised its holdings in Supernus Pharmaceuticals by 68.1% during the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock valued at $382,000 after buying an additional 4,729 shares during the period. AQR Capital Management LLC boosted its stake in Supernus Pharmaceuticals by 35.2% during the first quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock worth $2,791,000 after buying an additional 22,182 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Supernus Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock valued at $978,000 after acquiring an additional 1,297 shares during the last quarter. Millennium Management LLC increased its position in Supernus Pharmaceuticals by 370.5% during the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock valued at $4,695,000 after acquiring an additional 112,886 shares during the last quarter. Finally, Empowered Funds LLC raised its stake in shares of Supernus Pharmaceuticals by 16.0% in the first quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock valued at $1,573,000 after acquiring an additional 6,619 shares during the period.

Supernus Pharmaceuticals Trading Down 0.7%

NASDAQ SUPN opened at $53.87 on Monday. The company’s 50-day moving average price is $50.99 and its 200-day moving average price is $48.82. The stock has a market cap of $3.10 billion, a PE ratio of -79.22, a PEG ratio of 1.67 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a 12 month low of $29.16 and a 12 month high of $59.68.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on SUPN shares. Zacks Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Finally, Stifel Nicolaus raised their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $62.17.

Insider Transactions at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 710 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the completion of the sale, the vice president owned 14,508 shares of the company’s stock, valued at approximately $644,735.52. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Frank Mottola sold 20,000 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $50.41, for a total value of $1,008,200.00. Following the completion of the transaction, the senior vice president directly owned 15,496 shares in the company, valued at approximately $781,153.36. This trade represents a 56.34% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 25,185 shares of company stock valued at $1,268,022. 8.80% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.